Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Cambridge, Mass. – November 4,

The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe Disease research. This

The IPA Board was provided with the following statement regarding Biomarin’s BMN-701 study. If you have any questions or concerns

Please visit the IPA website to view the statement: http://worldpompe.org/index.php/news/590-ipa-statement-on-biomarin-s-june-9th-announcement-it-will-seek-to-out-license-bmn-701